176 related articles for article (PubMed ID: 17363548)
1. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
[TBL] [Abstract][Full Text] [Related]
2. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
4. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
Johns TG; McKay MJ; Cvrljevic AN; Gan HK; Taylor C; Xu H; Smyth FE; Scott AM
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):572-8. PubMed ID: 20638193
[TBL] [Abstract][Full Text] [Related]
5. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
6. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
Luwor RB; Zhu HJ; Walker F; Vitali AA; Perera RM; Burgess AW; Scott AM; Johns TG
Oncogene; 2004 Aug; 23(36):6095-104. PubMed ID: 15221011
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.
Bender H; Takahashi H; Adachi K; Belser P; Liang SH; Prewett M; Schrappe M; Sutter A; Rodeck U; Herlyn D
Cancer Res; 1992 Jan; 52(1):121-6. PubMed ID: 1727372
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas.
Tysnes BB; Haugland HK; Bjerkvig R
Invasion Metastasis; 1997; 17(5):270-80. PubMed ID: 9876221
[TBL] [Abstract][Full Text] [Related]
12. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
Fan Z; Baselga J; Masui H; Mendelsohn J
Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
[TBL] [Abstract][Full Text] [Related]
14. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
[TBL] [Abstract][Full Text] [Related]
15. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
16. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
Han Y; Caday CG; Nanda A; Cavenee WK; Huang HJ
Cancer Res; 1996 Sep; 56(17):3859-61. PubMed ID: 8752145
[TBL] [Abstract][Full Text] [Related]
17. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
[TBL] [Abstract][Full Text] [Related]
20. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]